+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sirolimus Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Sirolimus Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Sirolimus Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 198 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082729
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Sirolimus Market grew from USD 530.49 million in 2024 to USD 576.90 million in 2025. It is expected to continue growing at a CAGR of 8.51%, reaching USD 865.95 million by 2030.

Sirolimus has established itself as a pivotal immunosuppressive agent since its discovery, offering unparalleled efficacy in preventing organ rejection and treating various oncology indications. Over the past decade, its applications have broadened to include cardiovascular interventions through drug‐eluting stent coatings, while ongoing research explores its potential in metabolic and rare disease profiles. As healthcare systems worldwide grapple with rising treatment costs and complex regulatory landscapes, decision-makers seek a comprehensive understanding of sirolimus’s evolving role. This introduction outlines the pharmacological attributes, clinical milestones, and strategic imperatives that underscore the importance of sirolimus in modern therapeutics. By framing the broader context-ranging from pipeline innovations to market access dynamics-this section sets the stage for an in-depth executive summary tailored to experts and policy-shapers alike.

Transformative Shifts Reshaping the Sirolimus Landscape

The sirolimus market is undergoing transformative shifts driven by technological advances, regulatory reforms, and evolving patient needs. Precision medicine initiatives have accelerated biomarker-driven dosing strategies, ensuring optimal therapeutic windows while minimizing adverse effects. Concurrently, digital health platforms now enable real-time monitoring of sirolimus blood levels, strengthening adherence and outcome tracking. Moreover, strategic collaborations between pharmaceutical innovators and contract development organizations have streamlined scale-up processes, reducing time to market for novel formulations. In parallel, regulatory agencies have introduced accelerated pathways for immunomodulatory therapies, providing a clear framework for breakthrough designation. Consequently, stakeholders must navigate a landscape where scientific breakthroughs, policy changes, and patient-centric care converge to redefine how sirolimus is developed, approved, and delivered.

Assessing the Cumulative Impact of US Tariffs 2025 on Sirolimus

United States tariff policies slated for 2025 are poised to exert a cumulative impact on the sirolimus supply chain and cost structure. Increased duties on raw macrolide imports will amplify production expenses for manufacturers utilizing fermentation and isolation & purification techniques. This cost escalation will likely cascade through hospital pharmacies and retail outlets, prompting payers to reassess reimbursement frameworks for branded and generic sirolimus. Furthermore, heightened tariffs may incentivize sourcing from domestic fermentation facilities, accelerating local investments but also introducing capacity constraints during scale-up. In addition, research institutes engaged in preclinical studies and clinical trials could face higher material costs, potentially delaying Phase I through Phase III timelines. As a result, supply-chain resilience and strategic procurement will become paramount for companies seeking to mitigate the long-term implications of these tariff adjustments.

Key Segmentation Insights Driving Sirolimus Adoption

Deep segmentation analysis reveals distinct growth vectors and competitive differentiators across applications, formulations, and end users. In cardiology, sirolimus-coated stent technologies are driving demand amid rising cardiovascular disease prevalence, while oncology use in breast, liver, and renal cancer showcases the compound’s anti-proliferative versatility. Organ transplantation remains foundational, with kidney and liver transplant recipients-whether from deceased or living donors-continuing to rely on sirolimus for durable immunosuppression. Formulation strategies further delineate market opportunities: injectable forms dominate acute hospital settings, tablets-both immediate and sustained release-enhance outpatient compliance, and topical gels offer niche dermatological applications. End-user distinctions underscore that private hospitals and specialized clinics increasingly adopt advanced protocols, while research institutes push preclinical and clinical trials through robust pipeline portfolios. Patient type segmentation highlights that treatment regimens for seniors, young adults, and pediatric patients require tailored dosing paradigms to balance efficacy and safety. Distribution channels spanning hospital pharmacies, online outlets, and retail networks dictate accessibility, especially as online pharmacy models expand convenience. Dosage form differentiation between suspensions, syrups, caplets, and capsules informs patient adherence tactics, and each developmental phase, from Phase I trials through FDA approval, marks critical inflection points. Lastly, branded versus generic sirolimus dynamics shape pricing pressures and brand loyalty, compelling manufacturers to refine lifecycle management and value-added services.

Key Regional Insights Highlighting Growth Drivers and Hurdles

Regional dynamics play a pivotal role in shaping the sirolimus market trajectory. In the Americas, robust reimbursement frameworks and established transplant infrastructures sustain high utilization rates, although patent expiries have ushered in competitive generic entries. Europe, Middle East & Africa (EMEA) benefit from harmonized regulatory pathways under European directives, yet varying national health policies and pricing ceilings require adaptive market-access strategies. Meanwhile, the Asia-Pacific region is characterized by rapid healthcare modernization, rising transplant volumes, and expanding specialty care centers in markets such as China, India, and Japan. Nevertheless, challenges persist in emerging markets where supply-chain inefficiencies and regulatory heterogeneity may impede timely access. Consequently, companies must balance global scale with localized tactics to capitalize on region-specific demand drivers and navigate policy landscapes effectively.

Key Companies Shaping the Sirolimus Market Ecosystem

A constellation of established and emergent players is shaping the competitive environment for sirolimus. Biocon and Dr. Reddy’s Laboratories leverage robust fermentation capabilities and extensive generics portfolios to drive cost leadership, while Glenmark Pharmaceuticals and Intas Pharmaceuticals pursue differentiated formulations and delivery systems. Pfizer Inc. maintains a strong position through lifecycle management of branded sirolimus assets, complemented by strategic alliances with contract development partners such as ChemWerth Inc. and Concept Medical, Inc. Innovative biotech firms like Aadi Bioscience, Inc. focus on niche oncology applications, whereas Actiza Pharmaceutical Private Limited and Aurisco Pharmaceutical Co., Ltd. concentrate on regional market penetration. Torrent Pharmaceuticals Ltd. and Zydus Lifesciences Limited blend manufacturing scale with emerging-market expertise, and M.A. Med Alliance SA targets high-purity isolation & purification processes. Cordis Corporation and Delphis Pharmaceutical enhance portfolio breadth across cardiology and transplant segments, collectively driving a competitive paradigm centered on cost efficiency, formulation innovation, and regulatory agility.

Actionable Recommendations for Industry Leaders in Sirolimus

Industry leaders should adopt a multifaceted approach to sustain momentum in a dynamic market. Firstly, investing in domestic fermentation capacity and redundant supply lines will bolster resilience against tariff fluctuations. Secondly, advancing sustained-release and novel topical formulations can capture unmet needs in outpatient and dermatology care. Thirdly, forging early-stage partnerships with research institutes accelerates access to breakthrough indications in oncology and rare diseases, while proactive engagement with regulatory authorities streamlines approval pathways. Fourthly, optimizing digital health integrations for therapeutic monitoring will enhance patient outcomes and differentiate value propositions. Lastly, tailoring distribution models to online pharmacy growth and emerging-market channels ensures broader reach and mitigates traditional channel constraints.

Conclusion: Charting the Future of Sirolimus

Sirolimus’s enduring relevance stems from its versatile immunosuppressive and anti-proliferative mechanisms, underpinned by a robust pipeline and diverse application areas. Continued innovation in drug delivery, along with strategic supply-chain fortification, will define the market’s next chapter. Stakeholders equipped with granular segmentation intelligence, regional strategies, and competitor positioning can anticipate shifts and capitalize on opportunities. As tariff landscapes evolve and patient-centric care models mature, collaboration among manufacturers, payers, and regulators will be critical. This conclusion reaffirms sirolimus’s strategic importance and underscores the need for agile execution to navigate an increasingly complex global environment.

Market Segmentation & Coverage

This research report categorizes the Sirolimus Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Cardiology
    • Stent Coating
  • Oncology
    • Breast Cancer
    • Liver Cancer
    • Renal Cancer
  • Organ Transplantation
    • Kidney Transplants
      • Deceased Donor Transplants
      • Living Donor Transplants
    • Liver Transplants
  • Injections
  • Tablets
    • Immediate Release
    • Sustained Release
  • Topical Gels
  • Clinics
    • General Clinics
    • Specialized Clinics
  • Hospitals
    • Private Hospitals
    • Public Hospitals
  • Research Institutes
  • Adult Patients
    • Seniors
    • Young Adults
  • Geriatric Patients
  • Pediatric Patients
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Liquid Dosage Forms
    • Suspensions
    • Syrups
  • Solid Dosage Forms
    • Caplets
    • Capsules
  • Clinical Trials
    • Phase I Trials
    • Phase II Trials
    • Phase III Trials
  • FDA Approval
  • Preclinical Studies
  • Fermentation Process
  • Isolation & Purification
    • Chromatographic Techniques
    • Filtration Methods
  • Branded Sirolimus
  • Generic Sirolimus

This research report categorizes the Sirolimus Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Sirolimus Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Aadi Bioscience, Inc.
  • Actiza Pharmaceutical Private Limited
  • Aurisco Pharmaceutical Co., Ltd.
  • Biocon
  • ChemWerth Inc.
  • Concept Medical, Inc.
  • Cordis Corporation
  • Delphis Pharmaceutical
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Ltd.
  • M.A. Med Alliance SA
  • Pfizer Inc.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Sirolimus Market, by Application Area
8.1. Introduction
8.2. Cardiology
8.2.1. Stent Coating
8.3. Oncology
8.3.1. Breast Cancer
8.3.2. Liver Cancer
8.3.3. Renal Cancer
8.4. Organ Transplantation
8.4.1. Kidney Transplants
8.4.1.1. Deceased Donor Transplants
8.4.1.2. Living Donor Transplants
8.4.2. Liver Transplants
9. Sirolimus Market, by Formulation Type
9.1. Introduction
9.2. Injections
9.3. Tablets
9.3.1. Immediate Release
9.3.2. Sustained Release
9.4. Topical Gels
10. Sirolimus Market, by End-User
10.1. Introduction
10.2. Clinics
10.2.1. General Clinics
10.2.2. Specialized Clinics
10.3. Hospitals
10.3.1. Private Hospitals
10.3.2. Public Hospitals
10.4. Research Institutes
11. Sirolimus Market, by Patient Type
11.1. Introduction
11.2. Adult Patients
11.2.1. Seniors
11.2.2. Young Adults
11.3. Geriatric Patients
11.4. Pediatric Patients
12. Sirolimus Market, by Distribution Channel
12.1. Introduction
12.2. Hospital Pharmacies
12.3. Online Pharmacies
12.4. Retail Pharmacies
13. Sirolimus Market, by Dosage Form
13.1. Introduction
13.2. Liquid Dosage Forms
13.2.1. Suspensions
13.2.2. Syrups
13.3. Solid Dosage Forms
13.3.1. Caplets
13.3.2. Capsules
14. Sirolimus Market, by Developmental Phase
14.1. Introduction
14.2. Clinical Trials
14.2.1. Phase I Trials
14.2.2. Phase II Trials
14.2.3. Phase III Trials
14.3. FDA Approval
14.4. Preclinical Studies
15. Sirolimus Market, by Manufacturing Process
15.1. Introduction
15.2. Fermentation Process
15.3. Isolation & Purification
15.3.1. Chromatographic Techniques
15.3.2. Filtration Methods
16. Sirolimus Market, by Product Type
16.1. Introduction
16.2. Branded Sirolimus
16.3. Generic Sirolimus
17. Americas Sirolimus Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Sirolimus Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Sirolimus Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Aadi Bioscience, Inc.
20.3.2. Actiza Pharmaceutical Private Limited
20.3.3. Aurisco Pharmaceutical Co., Ltd.
20.3.4. Biocon
20.3.5. ChemWerth Inc.
20.3.6. Concept Medical, Inc.
20.3.7. Cordis Corporation
20.3.8. Delphis Pharmaceutical
20.3.9. Dr. Reddy's Laboratories Ltd.
20.3.10. Glenmark Pharmaceuticals Limited
20.3.11. Intas Pharmaceuticals Ltd.
20.3.12. M.A. Med Alliance SA
20.3.13. Pfizer Inc.
20.3.14. Torrent Pharmaceuticals Ltd.
20.3.15. Zydus Lifesciences Limited
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. SIROLIMUS MARKET MULTI-CURRENCY
FIGURE 2. SIROLIMUS MARKET MULTI-LANGUAGE
FIGURE 3. SIROLIMUS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL SIROLIMUS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL SIROLIMUS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL SIROLIMUS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SIROLIMUS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SIROLIMUS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 16. GLOBAL SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2030 (%)
FIGURE 18. GLOBAL SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 22. GLOBAL SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 24. GLOBAL SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS SIROLIMUS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS SIROLIMUS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES SIROLIMUS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES SIROLIMUS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA SIROLIMUS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA SIROLIMUS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. SIROLIMUS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. SIROLIMUS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. SIROLIMUS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SIROLIMUS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL SIROLIMUS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL SIROLIMUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL SIROLIMUS MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL SIROLIMUS MARKET SIZE, BY STENT COATING, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL SIROLIMUS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL SIROLIMUS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL SIROLIMUS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL SIROLIMUS MARKET SIZE, BY RENAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL SIROLIMUS MARKET SIZE, BY DECEASED DONOR TRANSPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL SIROLIMUS MARKET SIZE, BY LIVING DONOR TRANSPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL SIROLIMUS MARKET SIZE, BY LIVER TRANSPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL SIROLIMUS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL SIROLIMUS MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL SIROLIMUS MARKET SIZE, BY IMMEDIATE RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL SIROLIMUS MARKET SIZE, BY SUSTAINED RELEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL SIROLIMUS MARKET SIZE, BY TOPICAL GELS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL SIROLIMUS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL SIROLIMUS MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL SIROLIMUS MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL SIROLIMUS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL SIROLIMUS MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL SIROLIMUS MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL SIROLIMUS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL SIROLIMUS MARKET SIZE, BY SENIORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL SIROLIMUS MARKET SIZE, BY YOUNG ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL SIROLIMUS MARKET SIZE, BY GERIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL SIROLIMUS MARKET SIZE, BY PEDIATRIC PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL SIROLIMUS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL SIROLIMUS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL SIROLIMUS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL SIROLIMUS MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL SIROLIMUS MARKET SIZE, BY SYRUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL SIROLIMUS MARKET SIZE, BY CAPLETS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL SIROLIMUS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL SIROLIMUS MARKET SIZE, BY PHASE I TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL SIROLIMUS MARKET SIZE, BY PHASE II TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL SIROLIMUS MARKET SIZE, BY PHASE III TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL SIROLIMUS MARKET SIZE, BY FDA APPROVAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL SIROLIMUS MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL SIROLIMUS MARKET SIZE, BY FERMENTATION PROCESS, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL SIROLIMUS MARKET SIZE, BY CHROMATOGRAPHIC TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL SIROLIMUS MARKET SIZE, BY FILTRATION METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL SIROLIMUS MARKET SIZE, BY BRANDED SIROLIMUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL SIROLIMUS MARKET SIZE, BY GENERIC SIROLIMUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 87. AMERICAS SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 88. AMERICAS SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. AMERICAS SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 90. AMERICAS SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 91. AMERICAS SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 92. AMERICAS SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 93. AMERICAS SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 94. AMERICAS SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 95. AMERICAS SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 96. AMERICAS SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 97. AMERICAS SIROLIMUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 102. ARGENTINA SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 103. ARGENTINA SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 104. ARGENTINA SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 105. ARGENTINA SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. ARGENTINA SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 107. ARGENTINA SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 108. ARGENTINA SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 109. ARGENTINA SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 110. ARGENTINA SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 111. ARGENTINA SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 112. ARGENTINA SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 113. ARGENTINA SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 114. ARGENTINA SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 115. ARGENTINA SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 116. ARGENTINA SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 117. ARGENTINA SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 118. ARGENTINA SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 128. BRAZIL SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 129. BRAZIL SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 130. BRAZIL SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 131. BRAZIL SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 132. BRAZIL SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 133. BRAZIL SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 134. BRAZIL SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 135. BRAZIL SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 136. BRAZIL SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 137. BRAZIL SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 138. BRAZIL SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 139. BRAZIL SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 140. CANADA SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 141. CANADA SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 142. CANADA SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 143. CANADA SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 144. CANADA SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 145. CANADA SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 146. CANADA SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 147. CANADA SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. CANADA SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 149. CANADA SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 150. CANADA SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 151. CANADA SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 152. CANADA SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 153. CANADA SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 154. CANADA SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 155. CANADA SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 156. CANADA SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 157. CANADA SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 158. CANADA SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 159. CANADA SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 160. CANADA SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 161. MEXICO SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 162. MEXICO SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 163. MEXICO SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 164. MEXICO SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 165. MEXICO SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 166. MEXICO SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 167. MEXICO SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 168. MEXICO SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. MEXICO SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 170. MEXICO SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 171. MEXICO SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 172. MEXICO SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 173. MEXICO SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 174. MEXICO SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 175. MEXICO SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 176. MEXICO SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 177. MEXICO SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 178. MEXICO SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 179. MEXICO SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 180. MEXICO SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 181. MEXICO SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 182. UNITED STATES SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 183. UNITED STATES SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 184. UNITED STATES SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 185. UNITED STATES SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED STATES SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 187. UNITED STATES SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 188. UNITED STATES SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 189. UNITED STATES SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. UNITED STATES SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 191. UNITED STATES SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 192. UNITED STATES SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 193. UNITED STATES SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 194. UNITED STATES SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 195. UNITED STATES SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 196. UNITED STATES SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 197. UNITED STATES SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 198. UNITED STATES SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 199. UNITED STATES SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 200. UNITED STATES SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 201. UNITED STATES SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 202. UNITED STATES SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 203. UNITED STATES SIROLIMUS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 204. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 205. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 206. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 207. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 208. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 209. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 210. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 211. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 212. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 213. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 214. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 215. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 216. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 217. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 218. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 219. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 220. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 221. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 222. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 223. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 224. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 225. ASIA-PACIFIC SIROLIMUS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 226. AUSTRALIA SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 227. AUSTRALIA SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 228. AUSTRALIA SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 229. AUSTRALIA SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 230. AUSTRALIA SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 231. AUSTRALIA SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 232. AUSTRALIA SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 233. AUSTRALIA SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. AUSTRALIA SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 235. AUSTRALIA SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 236. AUSTRALIA SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 237. AUSTRALIA SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 238. AUSTRALIA SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 239. AUSTRALIA SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 240. AUSTRALIA SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 241. AUSTRALIA SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 242. AUSTRALIA SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 243. AUSTRALIA SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 244. AUSTRALIA SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 245. AUSTRALIA SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 246. AUSTRALIA SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 247. CHINA SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 248. CHINA SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 249. CHINA SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 250. CHINA SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 251. CHINA SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 252. CHINA SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 253. CHINA SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 254. CHINA SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. CHINA SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 256. CHINA SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 257. CHINA SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 258. CHINA SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 259. CHINA SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 260. CHINA SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 261. CHINA SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 262. CHINA SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 263. CHINA SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 264. CHINA SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 265. CHINA SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 266. CHINA SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 267. CHINA SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 268. INDIA SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 269. INDIA SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 270. INDIA SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 271. INDIA SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 272. INDIA SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 273. INDIA SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 274. INDIA SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 275. INDIA SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. INDIA SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 277. INDIA SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 278. INDIA SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 279. INDIA SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 280. INDIA SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 281. INDIA SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 282. INDIA SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 283. INDIA SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 284. INDIA SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 285. INDIA SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 286. INDIA SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 287. INDIA SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 288. INDIA SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 289. INDONESIA SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 290. INDONESIA SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 291. INDONESIA SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 292. INDONESIA SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 293. INDONESIA SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 294. INDONESIA SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 295. INDONESIA SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 296. INDONESIA SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 297. INDONESIA SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 298. INDONESIA SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 299. INDONESIA SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 300. INDONESIA SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 301. INDONESIA SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 302. INDONESIA SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 303. INDONESIA SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 304. INDONESIA SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 305. INDONESIA SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 306. INDONESIA SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 307. INDONESIA SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 308. INDONESIA SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 309. INDONESIA SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. JAPAN SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 311. JAPAN SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 312. JAPAN SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 313. JAPAN SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 314. JAPAN SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 315. JAPAN SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 316. JAPAN SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 317. JAPAN SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 318. JAPAN SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 319. JAPAN SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 320. JAPAN SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 321. JAPAN SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 322. JAPAN SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 323. JAPAN SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 324. JAPAN SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 325. JAPAN SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 326. JAPAN SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 327. JAPAN SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 328. JAPAN SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 329. JAPAN SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 330. JAPAN SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 331. MALAYSIA SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 332. MALAYSIA SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 333. MALAYSIA SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 334. MALAYSIA SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 335. MALAYSIA SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 336. MALAYSIA SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 337. MALAYSIA SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 338. MALAYSIA SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 339. MALAYSIA SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 340. MALAYSIA SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 341. MALAYSIA SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 345. MALAYSIA SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 346. MALAYSIA SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 347. MALAYSIA SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 348. MALAYSIA SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 349. MALAYSIA SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 350. MALAYSIA SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 351. MALAYSIA SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 352. PHILIPPINES SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 353. PHILIPPINES SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 354. PHILIPPINES SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 355. PHILIPPINES SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 356. PHILIPPINES SIROLIMUS MARKET SIZE, BY KIDNEY TRANSPLANTS, 2018-2030 (USD MILLION)
TABLE 357. PHILIPPINES SIROLIMUS MARKET SIZE, BY FORMULATION TYPE, 2018-2030 (USD MILLION)
TABLE 358. PHILIPPINES SIROLIMUS MARKET SIZE, BY TABLETS, 2018-2030 (USD MILLION)
TABLE 359. PHILIPPINES SIROLIMUS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 360. PHILIPPINES SIROLIMUS MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
TABLE 361. PHILIPPINES SIROLIMUS MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 362. PHILIPPINES SIROLIMUS MARKET SIZE, BY PATIENT TYPE, 2018-2030 (USD MILLION)
TABLE 363. PHILIPPINES SIROLIMUS MARKET SIZE, BY ADULT PATIENTS, 2018-2030 (USD MILLION)
TABLE 364. PHILIPPINES SIROLIMUS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 365. PHILIPPINES SIROLIMUS MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
TABLE 366. PHILIPPINES SIROLIMUS MARKET SIZE, BY LIQUID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 367. PHILIPPINES SIROLIMUS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2030 (USD MILLION)
TABLE 368. PHILIPPINES SIROLIMUS MARKET SIZE, BY DEVELOPMENTAL PHASE, 2018-2030 (USD MILLION)
TABLE 369. PHILIPPINES SIROLIMUS MARKET SIZE, BY CLINICAL TRIALS, 2018-2030 (USD MILLION)
TABLE 370. PHILIPPINES SIROLIMUS MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 371. PHILIPPINES SIROLIMUS MARKET SIZE, BY ISOLATION & PURIFICATION, 2018-2030 (USD MILLION)
TABLE 372. PHILIPPINES SIROLIMUS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 373. SINGAPORE SIROLIMUS MARKET SIZE, BY APPLICATION AREA, 2018-2030 (USD MILLION)
TABLE 374. SINGAPORE SIROLIMUS MARKET SIZE, BY CARDIOLOGY, 2018-2030 (USD MILLION)
TABLE 375. SINGAPORE SIROLIMUS MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 376. SINGAPORE SIROLIMUS MARKET SIZE, BY ORGAN TRANSPLANTATION, 2018-2030 (USD MILLION)
TABLE 377. SINGAPORE SIROLIMUS

Companies Mentioned

  • Aadi Bioscience, Inc.
  • Actiza Pharmaceutical Private Limited
  • Aurisco Pharmaceutical Co., Ltd.
  • Biocon
  • ChemWerth Inc.
  • Concept Medical, Inc.
  • Cordis Corporation
  • Delphis Pharmaceutical
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Limited
  • Intas Pharmaceuticals Ltd.
  • M.A. Med Alliance SA
  • Pfizer Inc.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Lifesciences Limited

Methodology

Loading
LOADING...

Related Topics

Related Reports

Sirolimus Market by Application, Distribution Channel - Global Forecast 2025-2030 - Product Image

Sirolimus Market by Application, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Sirolimus Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Sirolimus Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 176 Pages
  • Global
From
Organ Transplant Immunosuppressant Drugs Market Report 2025 - Product Image

Organ Transplant Immunosuppressant Drugs Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Immunosuppressants Market Report 2025 - Product Image

Immunosuppressants Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Immunomodulators - Market Insights, Competitive Landscape, and Market Forecast - 2030 - Product Image

Immunomodulators - Market Insights, Competitive Landscape, and Market Forecast - 2030

  • Report
  • 150 Pages
  • Global
From

About the Market

Sirolimus, also known as rapamycin, is an immunosuppressive drug used to prevent organ rejection in transplant patients. It works by inhibiting the activity of T-cells, which are responsible for attacking foreign bodies. Sirolimus is also used to treat certain types of cancer, such as lymphoma and Kaposi's sarcoma. It is often used in combination with other immunosuppressive drugs, such as cyclosporine and tacrolimus. Sirolimus is available in both oral and intravenous formulations. It is generally well-tolerated, with the most common side effects being nausea, vomiting, and diarrhea. It is also associated with an increased risk of infection and certain types of cancer. The sirolimus market is highly competitive, with several major players. These include Pfizer, Novartis, Merck, and Astellas. Other companies, such as Mylan and Teva, also offer generic versions of the drug. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.